RBD-based high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways
暂无分享,去创建一个
Y. Rudich | J. Zahradník | M. Roederer | P. Kwong | G. Schreiber | Shayne F. Andrew | J. Todd | K. Foulds | R. Seder | H. Andersen | Shir Marciano | B. Flynn | M. Nason | I-Ting Teng | Laurent Pessaint | Chunlin Li | Saran Bao | M. Gagne | A. Dodson | Alex Van Ry | C. Honeycutt | L. McCormick | Elizabeth McCarthy | D. R. Flebbe | Samantha J. Provost | M. Lewis | Anthony L. Cook | Daniel C Douek | D. Douek
[1] P. Bieniasz,et al. Pan-sarbecovirus prophylaxis with human anti-ACE2 monoclonal antibodies , 2023, Nature Microbiology.
[2] E. Pariani,et al. Nirmatrelvir treatment of SARS‐CoV‐2‐infected mice blunts antiviral adaptive immune responses , 2023, EMBO molecular medicine.
[3] N. Landau,et al. Prophylaxis and treatment of SARS-CoV-2 infection by an ACE2 receptor decoy in a preclinical animal model , 2023, iScience.
[4] Ashutosh Kumar Singh,et al. Optimizing variant-specific therapeutic SARS-CoV-2 decoys using deep-learning-guided molecular dynamics simulations , 2023, Scientific Reports.
[5] J. Zahradník,et al. Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant , 2023, bioRxiv.
[6] F. Agou,et al. Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages , 2022, bioRxiv.
[7] D. Douek,et al. Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster , 2022, The New England journal of medicine.
[8] M. Kiso,et al. Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB , 2022, The New England journal of medicine.
[9] G. Freeman,et al. Optimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivo , 2022, Science advances.
[10] J. Bukh,et al. Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system , 2022, Science advances.
[11] R. Sanjuán,et al. Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies , 2022, bioRxiv.
[12] Jin Ju Park,et al. Nirmatrelvir/Ritonavir Prescription Rate and Outcomes in Coronavirus Disease 2019: A Single Center Study , 2022, Infection & chemotherapy.
[13] H. Jäck,et al. Omicron sublineage BQ.1.1 resistance to monoclonal antibodies , 2022, The Lancet Infectious Diseases.
[14] Hao Tan,et al. Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir , 2022, bioRxiv.
[15] Seo Jung Hong,et al. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir , 2022, bioRxiv.
[16] S. Jonjić,et al. Anti-human ACE2 antibody neutralizes and inhibits virus production of SARS-CoV-2 variants of concern , 2022, iScience.
[17] S. Benenson,et al. Association of Receiving a Fourth Dose of the BNT162b Vaccine With SARS-CoV-2 Infection Among Health Care Workers in Israel , 2022, JAMA network open.
[18] T. Tripathi,et al. Hotspot residues and resistance mutations in the nirmatrelvir-binding site of SARS-CoV-2 main protease: Design, identification, and correlation with globally circulating viral genomes , 2022, bioRxiv.
[19] A. Sette,et al. Immunological memory to SARS‐CoV‐2 infection and COVID‐19 vaccines , 2022, Immunological reviews.
[20] Lauren M. Hickling,et al. Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure , 2022, Science.
[21] S. Hoehl,et al. Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes , 2022, Science Immunology.
[22] P. Maes,et al. Imprinted antibody responses against SARS-CoV-2 Omicron sublineages , 2022, bioRxiv.
[23] Y. Rudich,et al. Gelatin Stabilizes Nebulized Proteins in Pulmonary Drug Delivery against COVID-19 , 2022, ACS biomaterials science & engineering.
[24] K. Katoh,et al. An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo , 2022, Science Translational Medicine.
[25] Gheyath K Nasrallah,et al. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar , 2022, Nature Communications.
[26] M. Exline,et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study , 2022, BMJ.
[27] J. Mascola,et al. mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron , 2022, Cell.
[28] M. Baniecki,et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 , 2022, The New England journal of medicine.
[29] Liyuan Liu,et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages , 2022, Nature.
[30] Troy C. Hinkley,et al. Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine , 2022, bioRxiv.
[31] Xiangxi Wang,et al. Close relatives of MERS-CoV in bats use ACE2 as their functional receptors , 2022, bioRxiv.
[32] K. Swanson,et al. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera , 2022, Science.
[33] E. Shin,et al. T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the Omicron variant , 2022, Cellular & Molecular Immunology.
[34] S. Madhi,et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses , 2022, Cell.
[35] Mark M. Davis,et al. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination , 2022, Cell.
[36] G. Gao,et al. Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2 , 2022, Cell.
[37] M. Nussenzweig,et al. Plasma Neutralization of the SARS-CoV-2 Omicron Variant , 2021, The New England journal of medicine.
[38] L. Bekker,et al. Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa , 2021, The New England journal of medicine.
[39] D. Douek,et al. mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant , 2021, bioRxiv.
[40] J. Butterton,et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients , 2021, The New England journal of medicine.
[41] J. Mascola,et al. Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung , 2021, Cell.
[42] H. Jäck,et al. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic , 2021, Cell.
[43] Chaim A. Schramm,et al. Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine–boosted nonhuman primates , 2021, Science.
[44] J. Mascola,et al. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates , 2021, Science.
[45] K. Zatloukal,et al. Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor , 2021, bioRxiv.
[46] O. Dym,et al. SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution , 2021, Nature Microbiology.
[47] S. Elbashir,et al. mRNA-1273 Protects against SARS-CoV-2 Beta Infection in Nonhuman Primates , 2021, Nature Immunology.
[48] Christopher Allen,et al. Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants , 2021, Journal of virology.
[49] F. Rey,et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization , 2021, Nature.
[50] Shiho Tanaka,et al. An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants , 2021, Scientific Reports.
[51] Linqi Zhang,et al. Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species , 2021, Immunity.
[52] G. Barton,et al. Effects of common mutations in the SARS-CoV-2 Spike RBD domain and its ligand the human ACE2 receptor on binding affinity and kinetics , 2021, bioRxiv.
[53] Aaron M. Rosenfeld,et al. Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination , 2021, Science Immunology.
[54] A. Mirazimi,et al. A super-potent tetramerized ACE2 protein displays enhanced neutralization of SARS-CoV-2 virus infection , 2021, Scientific Reports.
[55] J. Mascola,et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.
[56] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.
[57] Steven Lin,et al. Humanized COVID‐19 decoy antibody effectively blocks viral entry and prevents SARS‐CoV‐2 infection , 2020, EMBO molecular medicine.
[58] D. Qu,et al. Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines , 2020, Proceedings of the National Academy of Sciences.
[59] Jorgen W. Nelson,et al. A Potent Anti-Malarial Human Monoclonal Antibody Targets Circumsporozoite Protein Minor Repeats and Neutralizes Sporozoites in the Liver. , 2020, Immunity.
[60] J. Dye,et al. Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2 , 2020, Science.
[61] J. Mascola,et al. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates , 2020, The New England journal of medicine.
[62] S. Pierce,et al. B cell memory: building two walls of protection against pathogens , 2019, Nature Reviews Immunology.
[63] Carole J Henry,et al. Remembrance of Things Past: Long-Term B Cell Memory After Infection and Vaccination , 2019, Front. Immunol..
[64] K. Foulds,et al. OMIP‐052: An 18‐Color Panel for Measuring Th1, Th2, Th17, and Tfh Responses in Rhesus Macaques , 2019, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[65] C. Andrews,et al. Genetic immunization in the lung induces potent local and systemic immune responses , 2010, Proceedings of the National Academy of Sciences.